Overview

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

Status:
NOT_YET_RECRUITING

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Hansoh BioMedical R&D Company

Treatments:

Irbesartan